ORIGINAL RESEARCH article
Front. Public Health
Sec. Infectious Diseases: Epidemiology and Prevention
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1535285
This article is part of the Research TopicTowards Control of the HIV epidemic: Trends in Epidemiology and Emerging Drug Resistance in the Integrase Inhibitor EraView all 6 articles
Prevalence of Low-Level Viremia in People Living with HIV/AIDS and Its Impact on Virological Failure in Guizhou Province, China
Provisionally accepted- 1Guiyang Public Health Jiuzhi Center, Guiyang, Guizhou Province, China
- 2School of Public Health, Guizhou Medical University, Guiyang, Guizhou Province, China
- 3Guizhou Centre for Disease Control and Prevention, Guiyang, Guizhou Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The frequency of low-level viremia (LLV) may vary across China. This study aims to analyze the epidemiological characteristics and related factors of LLV among HIV/AIDS patients in Guizhou Province from 2016 to 2022, and further analyze the impact of LLV on virological failure (VF).In this retrospective cohort study, we analyzed people living with HIV/AIDS whose demographic data, CD4 + T lymphocyte count, and viral load.To examine and compare the incidence of LLV at different levels, this study divided LLV into three groups based on previous research definitions: low-level LLV (LLLV) ranging from 50 to 199 copies/mL, medium-level LLV (MLLV) ranging from 200 to 399 copies/mL, and high-level LLV (HLLV) ranging from 400 to 999 copies/mL. Non-LLV was defined as never having experienced LLV. We compared the occurrence of LLV at different levels and frequencies, as well as the risk of virological failure (VF), using the Chi-square test. Non-conditional binary logistic regression analysis was used to identify factors influencing LLV.In total, 28,613 cases of infection were analyzed, with 33.72% (9,649/28,613) exhibiting LLV. The LLV proportion rates were 20.69%, 6.50%, and 6.48% in the low-level LLV (LLLV) (50-199 copies/mL), medium-level LLV (MLLV) (200-399 copies/mL), and high-level LLV (HLLV) (400-999 copies/mL) groups, respectively. The intermittent LLV (iLLV) and persistent LLV (pLLV) groups had LLV rates of 28.65% and 5.07%, respectively. The VF rates were 6.18%, 11.79%, and 13.70% in the LLLV, MLLV, and HLLV groups, respectively (P<0.001). The iLLV and pLLV groups had VF rates of 8.82% and 8.14%, respectively (P = 0.397). Multivariate logistic regression analysis revealed that the gender, ethnicity, age at antiretroviral therapy initiation, baseline CD4 + T lymphocyte count, and current treatment regimen were factors influencing the occurrence of LLV.The incidence of LLV among people living with HIV/AIDS treated with INSTI-sparing regimens in Guizhou Province is relatively high and is mainly influenced by factors such as age , CD4 + T lymphocyte count and treatment regimens. A comprehensive assessment of these factors is essential to implement targeted interventions that prevent LLV and enhance the effectiveness of antiretroviral therapy.
Keywords: AIDS, Antiretroviral therapy, Epidemiological characteristics, Guizhou Province, Influencing factors, Low-level viremia AIDS, antiretroviral therapy, Epidemiological characteristics, Guizhou Province, Influencing factors, Low-level viremia
Received: 27 Nov 2024; Accepted: 09 Jul 2025.
Copyright: © 2025 Zheng, Zha, Long, Zeng, Wang, Yao, Huang, Song, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yang Chen, Guizhou Centre for Disease Control and Prevention, Guiyang, 550004, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.